<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04544319</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GLCL002</org_study_id>
    <nct_id>NCT04544319</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin/Dapagliflozin 50/10 mg</brief_title>
  <official_title>Clinical Trial to Compare the Pharmacokinetics, Safety and Tolerability of the FDC of Gemigliptin/Dapagliflozin 50/10 mg to Each Component of Gemigliptin 50 mg and Dapagliflozin 10 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify bioequivalence between Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10&#xD;
      mg to Each Component of Gemigliptin 50 mg and Dapagliflozin 10 mg&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To identify bioequivalence between Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10&#xD;
      mg and each Component of Gemigliptin 50 mg and Dapagliflozin 10 mg Also we identify safety&#xD;
      and tolerance of FDC and each component&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Pre-dose (Day1 0 hour)</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 0.25hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 0.5hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 0.75hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 1hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 1.5hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 2hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 3hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 4hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 6hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 8hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 10hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 12hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 24hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 36hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 48hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gemigliptin and dapagliflozin AUClast and Cmax</measure>
    <time_frame>Day 1 72hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gemigliptin and dapagliflozin AUCinf</measure>
    <time_frame>Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gemigliptin and dapagliflozin Tmax</measure>
    <time_frame>Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gemigliptin and dapagliflozin t1/2</measure>
    <time_frame>Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gemigliptin and dapagliflozin CL/F</measure>
    <time_frame>Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gemigliptin and dapagliflozin V/F</measure>
    <time_frame>Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gemigliptin metabolite(LC15-0636) AUClast</measure>
    <time_frame>Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gemigliptin metabolite(LC15-0636) Cmax</measure>
    <time_frame>Pre-dose (Day1 0 h), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gemigliptin metabolite(LC15-0636) AUCinf</measure>
    <time_frame>Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gemigliptin metabolite(LC15-0636) t1/2</measure>
    <time_frame>Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gemigliptin metabolite(LC15-0636) metabolic ratio</measure>
    <time_frame>Pre-dose (Day1 0 hour), Day 1 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72 hour</time_frame>
    <description>each phase 17 times blood sampling, total 34 times blood sampling</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>T2DM</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Firstly, administrating each component Gemigliptin 50mg and dapagliflozin 10mg and after resting period administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Firstly, administrating Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg and after resting period administrating each component Gemigliptin 50mg and dapagliflozin 10mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zemiglo 50mg and Forxiga 10mg</intervention_name>
    <description>Each component of Gemigliptin 50mg QD and Dapagliflozin 10mg QD</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>zemiglo and Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg</intervention_name>
    <description>Fixed-dose Combinations of Gemigliptin/Dapagliflozin 50/10 mg QD</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>zemiglo and Forxiga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adults who are 19 years ~ 50 years when they are screened&#xD;
&#xD;
          2. weight: 55.0 kg ~ 90.0 kg and BMI: 18.0 kg/m2 ~ 30.0 kg/m2&#xD;
&#xD;
          3. Volunteers who understand the procedures of clinical trial and signed informed consent&#xD;
             form&#xD;
&#xD;
          4. Volunteers who are eligible decided by vital signs, physical examination, lab test and&#xD;
             12-lead ECG&#xD;
&#xD;
          5. Women of chlidbearing potential have negative results in pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Healtjy volunteers who don't have clinically significant disease such as liver&#xD;
             disease, severe renal disease, acute pancreatitis... etc&#xD;
&#xD;
          2. Drug Allergy in aspirin, NSAID, Anti-bacterial drugs&#xD;
&#xD;
          3. GI tract diseases which affect PK results and safety such as ulceritis, GERD, chron&#xD;
             disease...&#xD;
&#xD;
          4. Chronic urine track infection&#xD;
&#xD;
          5. Allergy history in sunset yellow 5 pigment and Fast green FCF (pigment)&#xD;
&#xD;
          6. galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption&#xD;
&#xD;
          7. These resluts are appeared when screening&#xD;
&#xD;
               -  ALT, AST &gt;= 1.5 Upper limit of normal range&#xD;
&#xD;
               -  HbsAg, anti-HCV, HIV Ag&amp;Ab positive&#xD;
&#xD;
               -  MDRD equation: eGFR&lt; 60 mL/min/1.73m2&#xD;
&#xD;
               -  QTcB&gt; 450 ms&#xD;
&#xD;
               -  Fasting serum glucose &lt; 70mg/dL or &gt;110mg/dL&#xD;
&#xD;
               -  HbA1c&gt;6.5%&#xD;
&#xD;
          8. SBP&lt;90mmHg or &gt;150mmHg, DBP &lt;60mmHg or &gt;100mmHg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>seunghwan Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>songyi park</last_name>
    <phone>02-6987-4195</phone>
    <email>songyi-park@lgchem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>clinical LG Chem</last_name>
    <email>lgclinical@lgchem.com</email>
  </overall_contact_backup>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

